CompletedNCT01749098
PF-04958242 and Ketamine Effects on Memory in Healthy Adults
About this title
A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers
Read the official source — NCT01749098Medication studyAges 21–45United StatesSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 21 years to 45 years.
- Listed locations
- New Haven and 1 more locationSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateDecember 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 29
- Sponsor
- Biogen
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 21 Years to 45 Years
- Official registry ID
- NCT01749098
- Official title
Show the full official title
A Randomized, Subject And Investigator Blinded, Sponsor Open Placebo Controlled, 2 Way, Crossover Phase 1b Study To Examine The Effects Of PF-04958242 On Ketamine Induced Cognitive Impairment In Healthy Male Volunteers
Get this study by email
Recruitment & locations
CompletedNew Haven · West Haven
Questions about this study
Who is behind this study?
The study sponsor is Biogen.
Did this study involve medication?
Yes. The study involved medication, including PF-04958242, ketamine and Placebo.
Who was this study for?
Listed age limits: 21 years to 45 years.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia